SRT3 Stock Analysis: Sartorius Aktiengesellschaft | XETRA
Medical Instruments & Supplies | XETRA, Germany | Market Cap: 17.443m EUR | 12M Return: 18.5% | DE0007165631 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.9M
EPS Trend: -16.5%
Qual. Beats: 0
Rev. Trend: 49.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sartorius Aktiengesellschaft is a German-headquartered supplier serving the biopharmaceutical industry through two main divisions: bioprocess solutions and lab products and services. Its portfolio spans analytical instruments (e.g., biolayer interferometry, surface plasmon resonance, live-cell imaging), cell culture technologies (bioreactors, media, reagents), fluid management, lab filtration and water purification, and process chromatography and filtration. End markets include life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industrial customers.
The company was founded in 1870 and is headquartered in Göttingen, Germany. As a major supplier of upstream and downstream bioprocessing equipment, Sartorius benefits from structural demand drivers such as the expansion of biologics manufacturing capacity, the rise of single-use technologies that replace stainless-steel systems, and growing investment in cell and gene therapy production.
- Bioprocess solutions revenue declines on biotech funding slowdown
- Cell and gene therapy expansion drives long-term growth
- Operating margins compress amid pricing pressure and inventory destocking
| Net Income: 171.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.69 > 1.0 |
| NWC/Revenue: 5.55% < 20% (prev 17.67%; Δ -12.12% < -1%) |
| CFO/TA 0.08 > 3% & CFO 734.4m > Net Income 171.4m |
| Net Debt (3.94b) to EBITDA (1.04b): 3.78 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.1m) vs 12m ago -0.14% < -2% |
| Gross Margin: 45.71% > 18% (prev 45.76%; Δ -0.05% > 0.5%) |
| Asset Turnover: 36.49% > 50% (prev 34.58%; Δ 1.91% > 0%) |
| Interest Coverage Ratio: 2.68 > 6 (EBIT TTM 620.0m / Interest Expense TTM 231.4m) |
| A: 0.02 (Total Current Assets 1.64b - Total Current Liabilities 1.44b) / Total Assets 9.60b |
| B: 0.27 (Retained Earnings 2.58b / Total Assets 9.60b) |
| C: 0.06 (EBIT TTM 620.0m / Avg Total Assets 9.81b) |
| D: 0.50 (Book Value of Equity 2.82b / Total Liabilities 5.60b) |
| Altman-Z'' = 1.97 = BBB |
| DSRI: 1.18 (Receivables 381.2m/313.4m, Revenue 3.58b/3.47b) |
| GMI: 1.00 (GM 45.76% / 45.71%) |
| AQI: 1.05 (AQ_t 0.57 / AQ_t-1 0.55) |
| SGI: 1.03 (Revenue 3.58b / 3.47b) |
| TATA: -0.06 (NI 171.4m - CFO 734.4m) / TA 9.60b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 253.00 with a total of 81,091 shares traded. Over the past week, the price has changed by +0.64%, over one month by +6.84%, over three months by +8.44% and over the past year by +18.47%.
Current recommended Stop Loss: 241.60 (which is 4.5% or 1.2 ATR below the current price).
Sartorius Aktiengesellschaft has no consensus analysts rating.
P/E Trailing = 89.258
P/E Forward = 39.2157
P/S = 4.8699
P/B = 6.189
P/EG = 0.9353
Revenue TTM = 3.58b EUR
EBIT TTM = 620.0m EUR
EBITDA TTM = 1.04b EUR
Long Term Debt = 3.49b EUR (from longTermDebt, last quarter)
Short Term Debt = 403.9m EUR (from shortTermDebt, last quarter)
Debt = 4.25b EUR (from shortLongTermDebtTotal, last quarter) + Leases 197.9m
Net Debt = 3.94b EUR (calculated: Debt 4.25b - CCE 306.9m)
Enterprise Value = 21.4b EUR (17.4b + Debt 4.25b - CCE 306.9m)
Interest Coverage Ratio = 2.68 (Ebit TTM 620.0m / Interest Expense TTM 231.4m)
EV/FCF = 73.01x (Enterprise Value 21.4b / FCF TTM 292.9m)
FCF Yield = 1.37% (FCF TTM 292.9m / Enterprise Value 21.4b)
FCF Margin = 8.18% (FCF TTM 292.9m / Revenue TTM 3.58b)
Net Margin = 4.79% (Net Income TTM 171.4m / Revenue TTM 3.58b)
Gross Margin = 45.71% ((Revenue TTM 3.58b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 47.50% (prev 46.10%)
Tobins Q-Ratio = 2.23 (Enterprise Value 21.4b / Total Assets 9.60b)
Interest Expense / Debt = 5.44% (Interest Expense 231.4m / Debt 4.25b)
Taxrate = 30.89% (125.0m / 404.7m)
NOPAT = 428.5m (EBIT 620.0m * (1 - 30.89%))
Current Ratio = 1.14 (Total Current Assets 1.64b / Total Current Liabilities 1.44b)
Debt / Equity = 1.51 (Debt 4.25b / totalStockholderEquity, last quarter 2.82b)
Debt / EBITDA = 3.78 (Net Debt 3.94b / EBITDA 1.04b)
Debt / FCF = 13.46 (Net Debt 3.94b / FCF TTM 292.9m)
Total Stockholder Equity = 2.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 171.4m / Total Assets 9.60b)
RoE = 6.28% (Net Income TTM 171.4m / Total Stockholder Equity 2.73b)
RoCE = 9.97% (EBIT 620.0m / Capital Employed (Equity 2.73b + L.T.Debt 3.49b))
RoIC = 5.11% (NOPAT 428.5m / Invested Capital 8.38b)
WACC = 7.16% (E(17.4b)/V(21.7b) * Re(7.99%) + D(4.25b)/V(21.7b) * Rd(5.44%) * (1-Tc(0.31)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.94 | Cagr: 0.41%
[DCF] Terminal Value 73.10% ; FCFF base≈405.9m ; Y1≈355.9m ; Y5≈287.6m
[DCF] Fair Price = 19.32 (EV 4.62b - Net Debt 3.94b = Equity 672.6m / Shares 34.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -16.47 | EPS CAGR: -2.23% | SUE: -0.48 | # QB: 0
Revenue Correlation: 49.86 | Revenue CAGR: 1.69% | SUE: -0.91 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.24 | Chg30d=+1.18% | Revisions=-62% | Analysts=6
EPS current Year (2026-12-31): EPS=5.25 | Chg30d=+0.04% | Revisions=-57% | GrowthEPS=+9.7% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=6.33 | Chg30d=+0.21% | Revisions=+29% | GrowthEPS=+20.5% | GrowthRev=+9.8%
[Analyst] Revisions Ratio: -44% (up=3, down=10)